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Summary
This consensus document provides evidence-based guidelines regarding the
evaluation of diabetic cardiovascular autonomic neuropathy (CAN) for
human research studies; the guidelines are the result of the work of the
CAN Subcommittee of the Toronto Diabetic Neuropathy Expert Group. The
subcommittee critically reviewed the limitations and strengths of the available
diagnostic approaches for CAN and the need for developing new tests for
autonomic function.
It was concluded that the most sensitive and specific approaches
currently available to evaluate CAN in clinical research are: (1) heart rate
variability, (2) baroreflex sensitivity, (3) muscle sympathetic nerve activity,
(4) plasma catecholamines, and (5) heart sympathetic imaging. It was also
recommended that efforts should be undertaken to develop new non-invasive
and safe CAN tests to be used in clinical research, with higher sensitivity
and specificity, for studying the pathophysiology of CAN and evaluating new
therapeutic approaches. Copyright  2011 John Wiley & Sons, Ltd.
Keywords diabetic neuropathy; heart rate variability; baroreflex sensitivity;
microneurography; catecholamines; cardiac imaging
Abbreviations: BRS – baroreflex sensitivity; CAN – cardiovascular auto-
nomic neuropathy; CARTs – cardiovascular autonomic reflex tests; DHPG – 3,
4-dihydroxyphenylglycol; HED – [11C]-metahydroxyephedrine; HRV – heart
rate variability; MIBG – [123I]-metaiodobenzylguanidine; MSNA – muscle
sympathetic nerve activity.
Introduction
This consensus document provides evidence-based guidelines regarding the
evaluation of diabetic cardiovascular autonomic neuropathy (CAN) for
human research studies; the guidelines are the result of the work of the
CAN Subcommittee of the Toronto Diabetic Neuropathy Expert Group.
The most sensitive and specific diagnostic tests currently available to
evaluate CAN in clinical research are: (1) heart rate variability (HRV),
(2) baroreflex sensitivity (BRS), (3) muscle sympathetic nerve activity
(MSNA), (4) plasma catecholamines, and (5) heart sympathetic imaging.
This article briefly reports the rationale for each CAN diagnostic test,
reviews critical evidence regarding the sensitivity and specificity of each test
in diabetes, and provides succinctly final recommendations.
A detailed description of the technical methods, their use in diabetes, and
additional references are reported in the online supplement attached to this
article (see Supporting information).
The methodology adopted for rating the quality of evidence and strength of
recommendations was that suggested by the American Academy of Neurology
[1] for diagnostic studies.
Copyright  2011 John Wiley & Sons, Ltd.
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Heart rate variability
Rationale
Heart rate is never completely stable. Continuous tonic,
phasic, and transient external and internal stimuli of
multiple origins affect heart rate to a variable but mea-
surable extent. Five different mechanisms have been
described: (1) sympathetic and parasympathetic effer-
ences to the sinus node; (2) neurohumoral influences
(e.g. catecholamines, thyroid hormones); (3) stretch of
the sinus node; (4) changes in local temperature; and
(5) ionic changes in the sinus node. Under resting con-
ditions, it can be assumed that the short-term HRV is
essentially determined by the first and third factors. The
sympathetic and parasympathetic stimuli directly influ-
ence heart rate and are responsible for a physiologic
variation in the heart rate, or HRV. The HRV can be
evaluated in the time and frequency domains.
Time domain measures of the normal R-R intervals
include the difference between the longest and shortest
R-R intervals, the standard deviation of 5-min average of
normal R-R intervals (SDANN), and the root-mean square
of the difference of successive R-R intervals (rMSSD).
Longer recordings (e.g. 24-h) allow the calculation of
additional indices, as the number of instances per hour in
which two consecutive R-R intervals differ by more than
50 ms over 24 h (pNN50). Essentially, all these indices
explore the parasympathetic activity.
In the frequency domain, the use of spectral analysis of
R-R interval (and other cardiovascular and respiratory
signals) allows a precise description of the different
fluctuations (see Supporting Information for technical
details) of these signals. The components of the HRV
obtained by spectral analysis provide information about
both the sympathetic and parasympathetic influences on
the heart [2,3].
It is traditionally accepted that the parasympathetic
system affects the overall variability (e.g. variance, total
power) and the sympathetic activity essentially influences
a rather narrow band around 0.1 Hz (low frequencies)
equivalent to a fluctuation of approximately 6 cycles/min.
However, the influence of these two factors on HRV is
markedly different. While the parasympathetic activity
influences the total amount of variability (the total
power of the spectrum), the sympathetic activity rather
than increasing or decreasing the fluctuations seems
to act like a low-pass filter. When the sympathetic
activity predominates (e.g. tilting, physical exercise),
to a large extent only the fluctuations at lower
frequency can influence the HRV, whereas the faster
perturbations (e.g. those determined by respiration)
cannot [4–8]. Accordingly, although respiration [which
normally generates heart rate fluctuations at higher
frequency, around 0.25 Hz, (high frequencies)] normally
increases in depth and frequency during sympathetic
activation, its influence on HRV is progressively smaller,
and consequently the low frequencies predominates in
the spectrum. However, the power in all frequency
components is reduced, as an effect of the global
reduction in HRV and in total power, induced by the
parasympathetic withdrawal and the increase in heart
rate. This explains the rather paradox phenomenon
whereby the low frequencies predominates (in relative
term) over the high frequencies during sympathetic
activation, but the amplitude (or the ‘power’) in low-
and high-frequency fluctuations actually decreases. With
extreme sympathetic activation and parasympathetic
withdrawal (that occurs in conditions like submaximal
exercise and severe heart failure), the overall variability
(or total power) is so small that the low-frequency
component can no longer be measured. Accordingly, it
is not surprising that the low-frequency power (when
expressed in absolute values) neither correlates with
direct measures of sympathetic activity (e.g. those
provided by microneurography) nor reflects sympathetic
changes, and it is now universally accepted that the
low frequencies absolute power does not reflect the
sympathetic activity.
Conversely, when measured in relative terms (i.e. as a
percentage of the global HRV), the relative proportion of
the low- over the high frequencies, provides a relative and
approximate indication of the sympathetic modulation to
the heart [9,10]. Thus, the sympathetic influences on
HRV can only be evaluated on the relative proportion
of HRV components [2]. Contributors to these low-
frequency oscillations in blood pressure and heart rate
include baroreflex activity and activity of an endogenous
oscillator in the brainstem or spinal chord [2–5].
The respiratory component (normally at high fre-
quency) is traditionally attributed to the parasympathetic
activity (respiratory sinus arrhythmia, between 12 and 18
breaths/min, or approximately at an average of 0.25 Hz).
Although the low-frequency fluctuations should not be
influenced by respiration, respiration is highly variable
and slow-breath-induced low frequencies are very fre-
quent, particularly during spontaneous breathing. These
spurious low frequencies explain the poor correlation
between direct measures of sympathetic activity and the
low frequencies, even when measured in relative terms,
during spontaneous breathing (at rest or during different
interventions) [11]. Conversely, by increasing or regu-
larizing the breathing rate the correlation between the
normalized low frequencies and the sympathetic activity
increases [11] as a result of the elimination of the res-
piratory artefacts on HRV. The simultaneous analysis of
respiration allows identification of periods without slow
breaths during spontaneous breathing. Only the analy-
sis performed on these data segments can be free from
artefacts.
The direct stretch of the sinus node has a very small
influence on the HRV of a healthy subject at rest
(2–4% of HRV) [12], but accounts for nearly 100%
of HRV in denervated hearts [13], severe CAN (due
to a permanent loss of autonomic modulation), or also
during transient withdrawal of autonomic modulation as
it occurs during submaximal exercise. This can be seen
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as a small respiration-linked fluctuation that correlates
positively with the increase in ventilation during physical
exercise. During extreme sympathetic activation and the
consequent reduced autonomic modulation of HRV, the
direct stretch of the sinus node remains the only evident
fluctuation [12]. This component should be taken into
account in severe CAN or during submaximal exercise.
Other fluctuations in lower frequencies (e.g. very-low
frequency components) are essentially caused by ‘exter-
nal’ factors (changes in activity and posture of ambulant
subjects [14]), and probably reflect parasympathetic activ-
ity, similar to the absolute power of the other frequency
components, the total power, or the time-domain indices.
To avoid important bias in the interpretation of HRV it
is recommended to perform spectral analysis with control
for respiration; to include adequate beat editing capability
to avoid the influence of artefacts and ectopic beats;
to understand the different significance of absolute and
relative components of HRV, to have clear indications as
regards to the different methodological approaches and
mathematical algorithms. Failing this, spectral analysis
cannot provide additional information as compared
with the simpler indices of global variability (standard
deviation of R-R intervals, variance, total power) and
results may be incorrect. This can occur when using some
commercially available equipments developed for Holter
24-h electrocardiogram recordings for short-term and
experimental data [15]. Conversely, when applied with
appropriate methodology, the spectral analysis provides
additional information to the time-domain indices, such
as information about sympathetic activation (though in
relative terms). Additionally, when beat-to-beat blood
pressure recording is obtained simultaneously with HRV,
it is possible to obtain an index of sympathetic activation
from the low-frequency power of blood pressure
[2,4–6,9]. The increase in low-frequency power of
blood pressure is particularly evident during sympathetic
activation induced by tilting [2,9] or physical exercise [6].
Based on studies using acceptable techniques, there
is evidence of reduced parasympathetic modulation of
heart rate in diabetes and also reduced modulation
of systolic blood pressure in the low-frequency region
[16–18] particularly after sympathetic stimulation in
response to tilting, or in the microcirculation [19].
As most of the cardiovascular autonomic reflex tests
(CARTs) essentially explore the parasympathetic activity
(as strongly suggested in the other paper on CAN in this
issue), there is no other simple test of sympathetic activity
capable of identifying early (functional or anatomic)
autonomic sympathetic abnormality [20]. CARTs are
considered the gold standard for CAN testing. Impaired
HRV time- and frequency-domain indices have been
reported in diabetic patients before CARTs abnormalities
arise. However, the few studies that assessed the
diagnostic accuracy against the reference standard of
CARTs found only fair results (see online supplement
for details). Time- and frequency-domain analysis of
24-h electrocardiogram recordings has documented
an abnormal nocturnal sympathetic predominance in
diabetic patients that was linked to blood pressure non-
dipping. In obese patients weight loss was associated with
an improvement in global HRV and in parasympathetic
HRV indices [21].
Highlights
• HRV testing is a clinically relevant measure in
addition to CARTs and provides key informa-
tion about autonomic – parasympathetic and sym-
pathetic – modulation of the cardio-vascular system.
• Analysis of HRV can be done using statistical indices
in the time and frequency domains.
• Time-domain indices of global HRV and total
spectral power of HRV represent the index of
parasympathetic activity, as well as the HRV
spectral power in the high-frequency region,
while the relative proportion (not the absolute
power) in the low frequencies of HRV provides
a relative measure of sympathetic modulation.
This interpretation should be made with cautions
if respiratory artifacts (slow breaths) cannot be
excluded.
• The parasympathetic nervous system also modu-
lates HRV in the high- and low-frequency regions,
and low-frequency power decreases or does not
change during sympathetic activation. Thus, the
absolute power in the low-frequency region should
not be used as an index of sympathetic activity.
• Application of the technique is critically dependant
upon understanding of the underlying physiology,
the mathematical analyses used, and the many
confounders and possible technical artefacts.
Confounders
• Misinterpretation of power spectrum due to irreg-
ular respiratory pattern and verbalization during
breathing, creating artefactual low frequencies and
false ‘sympathetic overactivity’.
• Lack of spectral decomposition algorithm when
using autoregressive methodology.
• Use of the absolute power of R-R interval low-
frequency spectral data as evidence of sympathetic
activity.
• In case of very low HRV (2–4% of total variability
found in healthy subjects) the interpretation of
spectral components is affected by the presence
of non-autonomic components in the respiratory
range.
• Other confounding factors (such as drugs) similar
as those reported for CARTs.
Recommendations
• The best approach to HRV testing involves
the analysis of electrocardiogram recordings in
Copyright  2011 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 2011; 27: 654–664.
DOI: 10.1002/dmrr
Investigation Methods for Cardiac Autonomic Function 657
conjunction with respiration and beat-to-beat blood
pressure recordings (level C).
• When respiration cannot be recorded, breathing
rate should be controlled (15 breaths/min), and
hyperventilation or slow deep breathing avoided
(level B).
• The subjects must not speak during recordings
(level C).
• The optimal recording time is 4–5 min during
well controlled rest. Longer times (7 min) may be
preferable if fast Fourier transform methods are
used and if frequent ectopics are to be edited. Long
uncontrolled recording times should be avoided
(level C).
• When testing is done under stable conditions,
autoregressive or fast Fourier transform methods
can be used.
• When fast changes are to be expected (e.g.
during interventions) autoregressive algorithms
are preferred, or alternatively special time-varying
techniques.
• Age-related reference curve should be obtained for
the healthy population in the same environment
and using the methodology adopted, construct 95%
confidence limits (level B).
• Other recommendations on confounding factors are
similar as those reported for CARTs.
• Used with the appropriate methodology HRV has
an increasingly important role in clinical research
and therapeutic trials.
During 24-h recordings:
• If the goal is to define the circadian pattern of
autonomic activity, long-duration spectra (e.g. 1 h)
and autoregressive algorithms are preferable.
• If the goal is to define relatively faster modifications,
shorter time windows (e.g. 5 min) are preferable.




Continuous changes in blood pressure are sensed in
different pressure-sensitive areas (particularly carotid
bifurcations and aortic arch) of the arterial tree. The
afferent fibres meet at the brainstem and elicit a double
response, vagal and sympathetic. An increase in blood
pressure reduces the firing of sympathetic vascular and
cardiac efferents and increases the firing of vagal cardiac
efferents, resulting in a rapid reduction in heart rate
and in blood pressure. The reduction in blood pressure
is due to both a reduction in cardiac output, which in
turn is caused by bradycardia, and to a slower direct
vasodilation secondary to sympathetic withdrawal. A
reduction in blood pressure induces opposite responses.
Thus, to correctly define the baroreflex function, one has
to consider both the vagal efferent activity (evidenced by
changes in heart rate in response to changes in blood
pressure), and the sympathetic efferent activity (mainly
directed to the arterial vessels). The latter response
cannot be easily studied in clinical environment, but
can be obtained for research purposes with simultaneous
recordings of MSNA [22] or, indirectly, by neck suction
[7]. In practice, the term ‘baroreflex sensitivity’ normally
applies to the cardiac-vagal arm, and to methods
measuring changes in heart rate in response to changes
in (systolic) blood pressure. The BRS is an interesting
approach as it combines information derived from both
heart rate and blood pressure.
The measurement of the cardiac-vagal arm BRS can be
done with several methods: drugs or physical manoeuvres
can be applied to modify blood pressure; alternatively,
spontaneous blood pressure variations can be used. In
all cases the response in heart rate to the changes in
blood pressure is quantified. These methods have been
described in detail in the online supplement section of
this article (see Supporting Information). None of the BRS
tests available today – based on drug-induced or physically
induced changes in blood pressure, spontaneous blood
pressure fluctuations with the sequences technique or
spectral analysis – have shown so far a definite advantage
over the others, or a clinically relevant difference.
Longitudinal studies have demonstrated that BRS
has important independent prognostic value in cardiac
patients [23–25] and in diabetic patients [26].
Although some observations in diabetic patients support
an early impairment of BRS before CARTs abnormalities
[27,28], very few studies have evaluated so far the diag-
nostic accuracy of BRS measures as compared with the
reference standard of CARTs with inconsistent results.
Thus, no definite conclusion is possible on the diagnostic
characteristics for CAN of BRS assessment, in particular
on its sensitivity. In patients without CAN an early stage
of functional BRS abnormalities [29] still responsive to
life-style intervention – physical training [30] or dietary
improvement and weight reduction [31] – has been docu-
mented. BRS assessment may warrant use for identifying
subjects at risk for CAN and also in clinical trials.
Highlights
• Cardiac vagal BRS assessment is an important
component of autonomic testing as it combines
information derived from both heart rate and blood
pressure.
• Cardiac vagal BRS is a widely recognised indepen-
dent prognostic index for cardiovascular mortality
and morbidity in the general – mainly cardiac – and
the diabetic population (class II).
• No definite conclusion is possible on the diagnostic
characteristics of BRS assessment (classes III–IV).
• The presence of early abnormalities with respect
to CARTs and their reversibility with appropriate
treatments warrant the clinical use of BRS in
Copyright  2011 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 2011; 27: 654–664.
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identifying subjects at risk for CAN and to test
potential therapeutic approaches (classes II–III).
• Pharmacological methods allow assessment of BRS
across a range of physiologically relevant blood
pressure and – when used with microneurogra-
phy – measurement of the sympathetic baroreflex.
But this invasive technique is limited to research
purposes.
• The methodology of BRS (in particular spontaneous
BRS) is simple and fast
• All BRS techniques require a dedicated beat-to-beat
non-invasive blood pressure monitor.
• None of the BRS tests today available have shown a
definite advantage over the others, nor a clinically
relevant difference (class II).
Confounders
• Fluctuations induced by drifts of the non-invasive
blood pressure monitors.
• Most methods need a large number of arbitrary
constraints imposed by the calculations that may
affect the results.
• Respiratory pattern: although BRS measures in
general do not need a strict control of respiratory
pattern, slow breathing increases BRS and reduces
sympathetic efferent drive [29,32]; therefore, some
feedback from respiration is necessary to correctly
interpret the results.
• Age-related reduction in BRS [33].
• Other confounding factors (e.g. drugs) are similar
as those for CARTs.
Recommendations
• If the spontaneous approach is adopted, it is
suggested to use a battery of methods based
on the simplest single 5 min recording procedure
(spontaneous BRS) and present the results in terms
of a central measure (average or median) (level C).
• Recording should be performed during sponta-
neous breathing for 4–5 min, under monitored
respiration, or during controlled breathing at 15
breaths/min (level C).
• Pre-filtering of the data improves the agreement
between methods and provides a more robust
estimate of BRS (level C).
• The recording time should be kept between 4
and 5 min of well-controlled rest. Avoid long
uncontrolled recording times (level C).
• The subjects must not speak during recordings
(level C).
• Age-related reference curves should be obtained for
the healthy population of in the same environment
and for the methodology adopted, and construct
95% confidence limits (level B).
• Other recommendations on confounding factors are
similar as those reported for CARTs.
Muscle sympathetic nerve activity
Rationale
MSNA, i.e. bursts of efferent sympathetic activity in
the skeletal muscle at rest or in response to various
physiological perturbations, can be directly recorded and
measured via microelectrodes inserted into a fascicle
of a distal sympathetic nerve to the skin or muscle
(microneurography) more commonly at the level of the
peroneal nerve. MSNA bursts are related to an inhibitory
effect of systole on the arterial baroreceptors, and the
burst frequency increases during reductions in blood
pressure and vice-versa.
Owing to its invasiveness and the time-consuming
nature of the procedure, MSNA is not indicated for routine
autonomic assessment. However, by being the most direct
measure of sympathetic activity it is an essential research
tool.
Increased resting MSNA and blunted responsiveness
to physiological hyperinsulinaemia or glucose ingestion
have been described in type 2 diabetic patients having
neuroadrenergic autonomic dysfunction, and resembles
insulin-resistant states and obesity. MSNA abnormalities
in these conditions reverse with weight loss [20,34]. In
contrast, type 1 diabetes is associated with a significant
decrease in the number of bursts, by about half
[35]. Although reproducibility is similar to non-diabetic
subjects, obtaining good quality recordings is much more
difficult in patients with diabetic polyneuropathy than in
non-diabetic subjects [20,36], presumably as a result of a
reduction in the conducting sympathetic nerve fibres.
Highlights
• The MSNA is the only method allowing direct
and continuous measurement of sympathetic nerve
traffic (class I).
• MSNA is the only method that can directly assess
the sympathetic vascular arm of the arterial or
cardiopulmonary baroreflex (class I).
• Type 1 diabetes appears to be associated with a
reduction of MSNA (class IV).
• In early type 2 diabetes, resting MSNA might
be increased, possibly due to hyperinsulinaemia
(class IV).
• The technique is difficult, invasive, time-consuming,
requires specialized trained operator and cannot be
repeated often in the same subject (class II).
Confounders
• Blood pressure variation
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• MSNA should not be routinely employed for the
diagnosis of CAN (level C).
• MSNA should be employed with standard CARTs
or for specific tests aimed at measuring vascular





The most important catecholamines in human plasma are
norepinephrine and epinephrine, both reflecting sympa-
thetic nervous activity: norepinephrine is released from
sympathetic nerve endings by exocytosis, a small pro-
portion reaching the systemic circulation [37]. Thus,
circulating norepinephrine mirrors whole-body sympa-
thetic activity when measured in systemic venous plasma.
Epinephrine is derived from sympathetic (preganglionic)
stimulation of the adrenal medulla and circulating
epinephrine therefore reflects the degree of sympathetic
activation of the adrenal medulla. Plasma norepinephrine
and epinephrine levels can respond differentially in
response to stressors; larger plasma norepinephrine
responses than epinephrine responses are found upon
exposure to cold, and larger plasma epinephrine responses
are found in response to glucoprivation and fainting.
Other catechols comprise the catecholamine precursor,
3,4-dihydroxy-L-phenylalanine and the main neuronal
metabolite of norepinephrine, 3,4-dihydroxyphenylglycol
(DHPG) [38].
Norepinephrine plasma appearance rate is in principle
the biochemical equivalent of MSNA. Norepinephrine
plasma appearance rate and clearance have been
determined in idiopathic autonomic neuropathy as well
as in diabetic CAN. While norepinephrine clearance is low
in idiopathic autonomic neuropathy, this was not the case
in CAN, and accordingly in diabetic CAN no additional
diagnostic power was added by the inclusion of [3H]-
norepinephrine kinetic studies [39]. Thus, catecholamine
kinetics is an interesting technique which may give
more information about catecholamine production and
clearance across different regions – but is unsuitable to
be used as a diagnostic tool yet. Plasma DOPA is not
related to sympathetic neuropathy and has a mixed
neuronal and non-neuronal origin. Plasma DHPG may
be a more sensitive marker of overall sympathetic
innervation than supine plasma norepinephrine [40], and
simultaneous measurement of norepinephrine and DHPG
yields more information than measurement of either
alone. Catecholamine assessment in diabetes showed in
general lower than normal responses to postural changes
[41], exercise [42,43], hypoglycaemia [44], and CARTs
[45–47]. A subnormal orthostatic increment in plasma
norepinephrine is a specific but not sensitive index
of baroreflex–sympathoneural failure or sympathetic
noradrenergic denervation.
Highlights
• Clinical investigations including catecholamine
determinations have contributed significantly to
the understanding of the pathophysiology of CAN
(class III). In the diagnostic context, the significance
has been less prominent, partly due to the limited
inclusion of the assays in clinical evaluations.
• Plasma catecholamine concentrations can indicate
sympathetic noradrenergic and adrenomedullary
hormonal system activity. Because levels of cat-
echols are extremely responsive to lifestyle fac-
tors such as posture, temperature, dietary intake,
medications, distress, and comorbidities, the clin-
ical diagnostic value of plasma levels of catechols
depends importantly on controlling or monitoring
these factors (class III).
• Whole-body plasma norepinephrine and epineph-
rine respond rather slowly (minutes) to different
physiological manoeuvres.
• During turnover studies, different regional nore-
pinephrine and epinephrine activities are ‘diluted’
into a large plasma pool, contributing to blunted
responses. Standardization of experimental condi-
tions is to a large extent prohibitive for clinical
routine purposes. In general, there is no neuro-
chemical index that specifically assesses cardiac
sympathetic innervation or function. This requires
measurement of rates of entry of norepinephrine
into the venous drainage of the heart, in turn
requiring right heart catheterization, measurement
of coronary sinus blood flow, and infusion of tracer-
labelled norepinephrine.
Confounders
• Plasma norepinephrine concentrations increase
with age. Thus, age matching is mandatory for
comparisons.
• Smoking increases sympathetic nervous activity
and catecholamine concentrations – 24 h tobacco
abstention is required for comparisons. Posture,
emotional stress, and ambient temperature all affect
catecholamine concentrations and should thus be
standardized.
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Recommendations
• In a number of experimental conditions, plasma
catecholamine measurements are mandatory. For
clinical routine diagnosis and staging of CAN the
usefulness of plasma catecholamine concentrations
is less obvious (level C).
• Plasma norepinephrine, epinephrine, and DHPG
concentrations should be measured when whole-
body sympathetic activity is assessed together with
other relevant physiological parameters (heart rate,
blood pressure, cardiac output, hormonal and
metabolic events).
Heart sympathetic imaging and heart
function tests
Rationale
Direct assessment of cardiac sympathetic innervation is
possible using radiolabelled catecholamines or sympath-
omimetic amines that are actively taken up by sympathetic
nerve terminals. The attraction of this technique is that
it allows direct characterization of the pattern of target
organ dysinnervation in diabetes. It is unclear whether
this modality can directly assess nerve terminal function.
An important limitation is that the imaging depends on
delivery of the agent by coronary perfusion. In patients
with coronary arterial or arteriolar narrowing, decreased
innervation can be difficult or impossible to distinguish
from decreased perfusion, without concurrent perfusion
imaging.
Although in principle, it is possible to directly assess
the integrity of both the parasympathetic as well as
the sympathetic nervous system, there has been a
paucity of research on parasympathetic imaging of the
heart. Cardiac sympathetic neuroimaging, before and
after administration of particular pharmacologic probes,
can assess specific aspects of neuronal function. This
combination has rarely been used.
Four tracers have been utilized to visualize the
sympathetic nervous innervation of the heart: [123I]-meta-
iodobenzylguanidine (MIBG), [11C]-meta-hydroxyephed-
rine (HED), 6-[18F] dopamine, and [11C]-epinephrine.
The washout rates from the myocardium of [11C]-
epinephrine or 6-[18F]-dopamine can give information on
vesicular integrity. In subjects with type 1 diabetes and
CAN, the washout rates of [11C]-epinephrine parallels
those of [11C]-HED, suggesting regional differences in
vesicular uptake or retention [48]. Causes of defective
tracer uptake or increased washout from the heart are a
matter of current research.
The interpretation of findings using sympathetic
neurotransmitter analogues is complicated by the fact
that alterations in sympathetic nervous system tone
may also affect the retention of these tracers, and
this fact is often not considered as an explanation for
the clinical findings. In the isolated rat heart model,
elevated norepinephrine concentrations in the perfusion
increased neuronal HED clearance rates consistent with
the concept that neuronal ‘recycling’ of HED can be
disrupted by increased synaptic norepinephrine levels
[49]. Alternatively at high norepinephrine concentrations,
non-neuronal uptake of HED into myocardial cells and
impaired retention may be an interfering factor.
Additionally, interpretation of early myocardial [123I]-
MIBG retention is complicated by increased body mass
index and diastolic blood pressure which have been
reported to reduce myocardial MIBG uptake [50].
Moreover, difficulties and delays in acquisition of
utilizable images can complicate the interpretation of
the measurement obtained. The delivery of tracers
is critically influenced by myocardial perfusion, so
myocardial retention of tracers should be performed with
a quantitative analysis of myocardial blood flow. This
can be performed using positron emission tomography
in order to derive a myocardial retention index [51].
However, although regional perfusion deficiencies can
be excluded using single photon emission computed
tomography, quantitative analysis of regional myocardial
perfusion cannot be performed. Additionally, myocardial
ischaemia or damage is also known to result in cardiac
denervation which may occur in the absence of alterations
in CARTs [52], whereas CAN is associated with impaired
vasodilatory capacity in response to adenosine [53].
Anoxic ischaemia severely decreases the efficiency of
vesicular sequestration and thus accelerates the loss of
radioactivity, giving the false impression of denervation.
Left ventricular dysfunction in diabetes has also been
reported to reduce [123I]-MIBG retention and increased
washout rate [54].
Highlights
• Scintigraphic tracers directly assess the structural
integrity of the sympathetic nervous system supply
to the heart (class III).
• [123I]-MIBG scanning and single photon emission
computed tomography are widely used and avail-
able at most secondary care institutions; however,
MIBG scanning is approved and reimbursed for
evaluation of pheochromocytoma and so far not for
evaluation of cardiac sympathetic innervation.
• Most data relate to the evaluation of cardiac
sympathetic integrity; few studies evaluate the
respiratory system.
• The relationships of deficits in tracer uptake/wash-
out to sympathetic neuronal integrity and function
are poorly understood: current tracers may not
be the most optimum. Combined neuroimaging-
pharmacologic approaches are required.
• Scintigraphic data correlates with HRV testing,
but have greater sensitivity to detect changes in
sympathetic neuronal structure and/or function
[55,56] (class III).
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• Scintigraphic data correlate with indices of myocar-
dial perfusion and left ventricular dysfunction in
type 1 diabetes [57] (class III).
• Limited studies demonstrate that decreased ‘uptake’
and excessive ‘washout’ of MIBG-derived radioactiv-
ity is an adverse prognostic finding in a spectrum of
conditions including diabetes and that scintigraphic
data are affected by the quality of glucose control
[58–60] (class III).
• Cost of scintigraphic studies is considerable.
Confounders
• Parasympathetic tracers are not yet generally
available.
• [11C]-HED and 6-[18F]-dopamine positron emission
tomography have limited availability and are not
reimbursed.
• Damage to the myocardium and left ventricular
dysfunction interferes with tracer uptake and
washout independently of changes in CARTs.
• Regional myocardial [123I]-MIBG ‘uptake’ is semi-
quantitative and not a clean index of neuronal
uptake, which occurs extremely rapidly.
• [123I]-MIBG retention is affected by body mass
index, diastolic blood pressure, and local factors
which influence the tracer uptake and retention.
• Delivery of tracers is critically influenced by
myocardial perfusion (myocardial retention of
tracers should be performed with quantitative
analysis of myocardial blood flow).
• The effects of the following on the kinetics of
myocardial tracer retention are poorly understood:







• Methodology for the assessment of sympathetic
integrity is not standardized.
• Normative values have not been developed.
Recommendations
• Scintigraphic studies should not be routinely
employed for the diagnosis of CAN and should be
utilized in concert with standard CARTs (level C).
• Scintigraphic studies are extremely valuable in the
identification of sympathetic noradrenergic dener-
vation as a mechanism of neurogenic orthostatic
hypotension (level B).
• [123I]-MIBG single photon emission computed
tomography offers semi-quantitative assessment
and [11C]-HED, 6-[18F]-dopamine, and [11C]-
epinephrine positron emission tomography offer
quantitative assessment of cardiac sympathetic
integrity (level B).
• There is no standardized methodology for scinti-
graphic assessment of cardiac sympathetic integrity
and only limited data on the reproducibility exist
(level C).
• Scintigraphic tracer uptake is affected by myocar-
dial perfusion, and tracer retention is affected by
available energy for the active neuronal and vesic-
ular uptake transporters (level C).
• The results of scintigraphy should be compared with
an appropriate control population (level C).
• Scintigraphic studies offer good sensitivity to detect
sympathetic neuronal loss in the heart (level C).
• Scintigraphy is appropriate to explore the effects
of sympathetic denervation on cardiac physiology,
metabolism, and function (level C).
• Scintigraphy is useful as a marker of cardiac
sympathetic denervation in cross-sectional and
longitudinal research studies (level C).
Conclusions
Assessment of HRV and BRS are the most widely
used and readily available diagnostic tests for CAN in
clinical research. They offer the possibility to provide
new information about the pathophysiology of autonomic
dysfunction in diabetes, to clarify the natural history
of CAN with regard to the early autonomic abnormalities
observed in diabetes and pre-diabetes, and to obtain more
sensitive and comprehensive end-points in clinical trials
in CAN. They might also be used in clinical practice
in secondary care institutions to provide additional
early and prognostic information to current CARTs. To
obtain meaningful results, however, they need control of
confounding factors, strict standardization with regard to
respiration and blood pressure recording and to comply
with various technical requirements (in particular for HRV
testing).
Scintigraphic investigations may be available at most
secondary care institutions and are potentially useful in
longitudinal research studies. The role of MSNA and
catecholamine assessment as end-points in clinical trials,
as already applied in life-style intervention trials in
obesity, needs to be further elucidated. Conversely, these
techniques are the gold reference for assessing the role of
the sympathetic nervous system in quantitative terms.
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